Unknown

Dataset Information

0

Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.


ABSTRACT: Activation of tyrosine kinase 2 (TYK2) contributes to the aberrant survival of T-cell acute lymphoblastic leukaemia (T-ALL) cells. Here we demonstrate the anti-leukaemic activity of a novel TYK2 inhibitor, NDI-031301. NDI-031301 is a potent and selective inhibitor of TYK2 that induced robust growth inhibition of human T-ALL cell lines. NDI-031301 treatment of human T-ALL cell lines resulted in induction of apoptosis that was not observed with the JAK inhibitors tofacitinib and baricitinib. Further investigation revealed that NDI-031301 treatment uniquely leads to activation of three mitogen-activated protein kinases (MAPKs), resulting in phosphorylation of ERK, SAPK/JNK and p38 MAPK coincident with PARP cleavage. Activation of p38 MAPK occurred within 1 h of NDI-031301 treatment and was responsible for NDI-031301-induced T-ALL cell death, as pharmacological inhibition of p38 MAPK partially rescued apoptosis induced by TYK2 inhibitor. Finally, daily oral administration of NDI-031301 at 100 mg/kg bid to immunodeficient mice engrafted with KOPT-K1 T-ALL cells was well tolerated, and led to decreased tumour burden and a significant survival benefit. These results support selective inhibition of TYK2 as a promising potential therapeutic strategy for T-ALL.

SUBMITTER: Akahane K 

PROVIDER: S-EPMC5384871 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.

Akahane Koshi K   Li Zhaodong Z   Etchin Julia J   Berezovskaya Alla A   Gjini Evisa E   Masse Craig E CE   Miao Wenyan W   Rocnik Jennifer J   Kapeller Rosana R   Greenwood Jeremy R JR   Tiv Hong H   Sanda Takaomi T   Weinstock David M DM   Look A Thomas AT  

British journal of haematology 20170314 2


Activation of tyrosine kinase 2 (TYK2) contributes to the aberrant survival of T-cell acute lymphoblastic leukaemia (T-ALL) cells. Here we demonstrate the anti-leukaemic activity of a novel TYK2 inhibitor, NDI-031301. NDI-031301 is a potent and selective inhibitor of TYK2 that induced robust growth inhibition of human T-ALL cell lines. NDI-031301 treatment of human T-ALL cell lines resulted in induction of apoptosis that was not observed with the JAK inhibitors tofacitinib and baricitinib. Furth  ...[more]

Similar Datasets

| S-EPMC3980736 | biostudies-literature
| S-EPMC7761059 | biostudies-literature
| S-EPMC4974466 | biostudies-literature
2017-07-12 | GSE78234 | GEO
| S-EPMC4693965 | biostudies-literature
| S-EPMC3816716 | biostudies-literature
| S-EPMC4991939 | biostudies-literature
| S-EPMC4317519 | biostudies-literature
| S-EPMC8398498 | biostudies-literature
| S-EPMC3960632 | biostudies-literature